Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West

Allaire, Manon; Hajj, Weam El; Brichler, Ségolène; Diallo, Kadiatou; Fanica, Daniela; Blaise, Lorraine; N’Kontchou, Gisèle; Grando, Véronique; Arbadi, F.; Nahon, Pierre; Ziol, Marianne; Nault, Jean‐Charles; Ganne-Carrié, Nathalie

doi:10.1016/j.clinre.2020.03.030

Cited by 6 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Introduction of screening programmes for patients with chronic liver disease not yet diagnosed with liver cirrhosis is repeatedly discussed in the literature [ 33 , 34 , 35 ]. The current guidelines also indicate a great need for research to establish a clear approach [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Penzkofer

Mittler

Heinrich

et al. 2022

JCM

View full text Add to dashboard Cite

Liver cirrhosis is the most common risk factor for the development of hepatocellular carcinoma (HCC). However, 10 to 15% of all HCC arise in a non-cirrhotic liver. Few reliable data exist on outcome after liver resection in a non-cirrhotic liver. The aim of this single-centre study was to evaluate the outcome of resection for HCC in non-cirrhotic liver (NC-HCC) and to determine prognostic factors for overall (OS) and intrahepatic recurrence-free (RFS) survival. From 2008 to 2020, a total of 249 patients were enrolled in this retrospective study. Primary outcome was OS and RFS. Radiological and pathological findings, such as tumour size, number of nodules, Tumour-, Nodes-, Metastases- (TNM) classification and vascular invasion as well as extent of surgical resection and laboratory liver function were collected. Here, 249 patients underwent liver resection for NC-HCC. In this case, 50% of patients underwent major liver resection, perioperative mortality was 6.4%. Median OS was 35.4 months (range 1–151 months), median RFS was 10.5 months (range 1–128 moths). Tumour diameter greater than three centimetres, multifocal tumour disease, vascular invasion, preoperative low albumin and increased alpha-fetoprotein (AFP) values were associated with significantly worse OS. Our study shows that resection for NC-HCC is an acceptable treatment approach with comparatively good outcome even in extensive tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Penzkofer

Mittler

Heinrich

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In a retrospective analysis of patients with heterogenous HCC etiologies, African Americans had 2 times higher odds of unrecognized cirrhosis, and less likelihood to undergo HCC surveillance compared to Caucasian peers, agreeing with findings from a contemporary French case series. 24 , 39 In the latter study, where most participants (60%) were from Africa, 14% of HBV-related HCC developed in noncirrhotic liver, with significantly lower age among patients without cirrhosis compared to those with cirrhosis (51 vs. 58 y, respectively). 39 …”

Section: Discussionmentioning

confidence: 94%

Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis

Kamal,

Ingre,

Stål

et al. 2023

Hepatology Communications

View full text Add to dashboard Cite

Background: The international recommendations of HCC surveillance for African-born persons with chronic hepatitis B (CHB) without cirrhosis are divergent, probably due to scarce data on incidence rate (IR) for HCC. Methods: We assembled a cohort with prospectively collected data of Swedish residents of African origin with diagnosed CHB without cirrhosis at baseline from 1990 to 2015. Data from nationwide registers were used to calculate the sex-specific IR and IR ratio (incidence rate ratios) in relation to age, comorbidities, and birth region, using a generalized linear model with a log-link function and Poisson distribution. Results: Among 3865 African-born persons with CHB without cirrhosis at baseline, 31 (0.8%; 77.4% men) developed HCC during a median of 11.1 years of follow-up, with poor survival after HCC diagnosis. The mean age at HCC diagnosis was 46.8 (SD±14.7; range 23–79) in men. HCC IR exceeded the recommended surveillance threshold of 0.2%/year at ages 54 and 59 years in men and women, respectively, and at ages 20–40 years if HCV or HDV co-infection was present. African-born men with CHB had an incidence rate ratios of 10.6 (95% CI 4.4–31.5) for HCC compared to matched African-born peers without CHB, and an incidence rate ratios of 35.3 (95% CI 16.0–88.7) compared to a matched general population. Conclusions: African-born men with CHB without cirrhosis reached an IR of 0.2%/year between 50 and 60 years, and at younger ages if HCV or HDV co-infection was present. Our findings need further confirmation, and new cost-effectiveness analyses specific for young populations are needed, to provide personalized and cost-effective HCC surveillance.

show abstract

“…The disease, which is related to hepatic viral infections (HCV and HBV), occurs mainly in Asia, with nearly half of the cases in China. Therefore, diagnosis and treatment of HCC constitute a major challenge for healthcare workers [12]. There are limited treatments and a poor prognosis for HCC patients, with a median survival of about 1 year.…”

Section: Discussionmentioning

confidence: 99%

Concomitant administration of lenvatinib and camrelizumab for the treatment of hepatocellular carcinoma, and its effect on hepatocellular carcinoma control

Liu¹,

Zhang²,

Wang³

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To study the efficacy of combined use of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC) therapy, and its impact on disease control rate (DCR). Methods: The medical records of 92 HCC patients treated at the Oncology Department of The People’s Hospital of Dongying, Dongying, China (April 2019-April 2020), were chosen for analysis, and assigned into study group (SG, n = 46) and reference group (RG, n = 46) based on odd and even hospital admission no. All patients received specific routine treatments. In addition, SG was treated with lenvatinib in combination with camrelizumab. After treatment, liver function and levels of serum tumor markers were determined. Results: Compared with RG, SG had significantly lower levels of liver function indices {alanine aminotransferase (ALT), total bilirubin (TBiL), and aspartate aminotransferase (AST)} and lower levels of serum tumor markers {alpha-fetoprotein (AFP), alpha-fetoprotein variant (AFP-L3) and Golgi protein 73 (GP73)} (p < 0.001); higher DCR (p < 0.05), lower score in Eastern Cooperative Oncology Group (ECOG), and higher Karnofsky (KPS) score (p < 0.001). Conclusion: The combined use of lenvatinib and camrelizumab may be a reliable strategy for reducing serum tumor marker levels in HCC patients, improving liver function and patients’ performance status, and enhancing DCR.

show abstract

Prior surveillance and antiviral treatment improve the prognosis of HCC developed in HBV patients in the West

Cited by 6 publications

References 18 publications

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosis

Concomitant administration of lenvatinib and camrelizumab for the treatment of hepatocellular carcinoma, and its effect on hepatocellular carcinoma control

Contact Info

Product

Resources

About